GlassScriptPhysician profile
Hussein A Azzam
NPI 1144688854
$7,302.73
in general payments reported to CMS, 2019-2025
27 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $682 · 2021: $1,144 · 2022: $932 · 2023: $977 · 2024: $1,467 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.12 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,415.41 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,227.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $914.12 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $823.68 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $532.51 | 2019-2025 | |
| Kaleo, INC. | $371.28 | 2020-2024 | Auvi-Q |
| Genentech USA, INC. | $276.34 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $240.33 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $200.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.83 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $130.77 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.61 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $92.14 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $91.83 | 2021-2023 | |
| Octapharma USA, INC. | $78.78 | 2023-2024 | Panzyga, Cutaquig |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $73.25 | 2022-2024 | Adbry |
| Organon LLC | $73.05 | 2025 | Vtama |
| Amgen INC. | $73.00 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $68.92 | 2020-2023 | Xembify |
| Pfizer INC. | $63.97 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $61.90 | 2023-2025 | Ryaltris |
| Abbvie INC. | $40.72 | 2023 | Rinvoq |
| Merck Sharp & Dohme LLC | $35.84 | 2021-2023 | |
| Tersera Therapeutics LLC | $28.99 | 2024 | Quzyttir |
| Dermavant Sciences, INC. | $25.05 | 2024 | Vtama |
| Lilly USA, LLC | $22.26 | 2025 | Ebglyss |
| Phadia US INC. | $19.04 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Azzam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.